TRACON Pharmaceuticals Initiates Phase 1b Study of TRC105

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TRACON Pharmaceuticals Initiates Phase 1b Study of TRC105 in Patients With Metastatic Renal Cell Carcinoma

SAN DIEGO, Sept. 23, 2013 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced the initiation of dosing in a clinical trial evaluating the combination of TRC105 and axitinib (Inlyta®, Pfizer), a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI), to treat patients with metastatic renal cell carcinoma. TRC105, a novel monoclonal antibody to endoglin (CD105), is being studied in multiple clinical trials in combination with agents that target the VEGF pathway.

"Renal cell carcinoma is an angiogenesis driven tumor and despite multiple products approved to treat the disease, resistance to treatment remains a serious challenge," said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. "Combining TRC105 with axitinib in this study builds upon our clinical experience in combining TRC105 with bevacizumab (Avastin®, Genentech/Roche), presented at ASCO in June, where data was presented indicating that the combination  of TRC105 and anti-VEGF treatment was well-tolerated and shrank tumors in patients who failed prior treatment with VEGF inhibitors. This study is part of a broad development program for TRC105 that includes two ongoing randomized Phase 2b studies with Avastin® and a trial in combination with VEGF TKI treatment in sarcoma."

The clinical trial is a multicenter, open-label, nonrandomized, Phase 1b, dose-finding study of TRC105 in combination with standard dose axitinib in patients with advanced renal cell carcinoma. For additional information on this clinical trial, please visit the clinicaltrials.gov identifier NCT01806064.

About TRC105

TRC105 is a novel, first-in-class, clinical stage antibody to endoglin (CD105), an endothelial cell receptor that is essential for the process of new blood vessel formation called angiogenesis. TRC105 is currently being studied in multiple clinical trials in cancer patients, sponsored by both TRACON and the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) and is expected to complement VEGF inhibitor therapies (including Avastin®). TRC105 is also expected to complement VEGF inhibitor treatments (e.g., Eylea® and Lucentis®) in age-related macular degeneration. For more information about the clinical trials, please visit TRACON's website at http://www.traconpharma.com/clinical_trials.php .

About TRACON

TRACON Pharmaceuticals develops targeted therapies for people with cancer and age-related macular degeneration. The current pipeline includes two clinical-stage product candidates, each addressing a unique cellular process, that are expected to complement currently available therapies. TRACON aims to develop effective and well-tolerated treatments for underserved populations with the ultimate goal of enhancing survival and quality of life. To learn more about the company and its products, visit TRACON's website at www.traconpharma.com .

Casey Logan Chief Business Officer (858) 550-0780 ext. 236

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Revenue Missteps Shake Semiconductor Stocks

Updated Category News Views 8

Nervous Times for Semiconductor Stocks When the semiconductor sector started October like a high-speed train, I thought we might sail through this month without hitting turbulence. But then, in trotted some shaky AI revenue numbers, and bam, the whole sector took a hit off its October highs. The semiconductor stocks, led by giants like Taiwan Semiconductor Manufacturing...

Continue Reading
Kailas Campaign Binds Climbers with Gear, Trust

Updated Category News Views 5

Embracing the Spirit of Climbing Connections Alright, so when's the last time you saw a brand digging into the human side of one rugged sport like climbing? That's where Kailas steps in, pulling us beyond gear talk into the trust and camaraderie that defines climbing. Their latest effort—dubbed “Stay Warm, Stay Together”—goes beyond mere technical prowess by...

Continue Reading
KAPSARC Drives Energy Dialogue at WPC in Riyadh

Updated Category News Views 9

Defining Energy Horizons in Riyadh Mark those calendars, because as the global energy crowd descends on Riyadh from October 11 to 15, 2026, KAPSARC steps into the spotlight. As the National Partner at the 25th World Petroleum Congress (WPC), they're not just warming the bench—they're playing every position, shaking up the field of energy. Paving the Pathways with...

Continue Reading
Amap, Sands China Unleash Tutu Robots for Resort Duty

Updated Category News Views 6

Tutu Robots Usher in a New Technological Era for Sands China Alright, let's dive into some tech that feels out of a sci-fi movie and see what Sands China and Amap have cooked up as they introduce the Tutu robot dogs to Sands Resorts Macau. These aren't your run-of-the-mill gadgets—they're futuristic tour guides ready to rewire visitor experiences. The delivery ceremony...

Continue Reading
tm:rw Revolutionizes Retail with Live TikTok Studios

Updated Category News Views 4

tm:rw Takes a Bold Step into Social Commerce Throw out whatever you've thought about traditional brick-and-mortar retail because tm:rw isn't just bending the rules—it's burning the book. Launching nine branded studio spaces at their Times Square flagship, tm:rw is blending live streaming with in-person shopping, all in sync with TikTok Shop. The experience is less about...

Continue Reading
Kexing Biopharm Expands Global Reach at CPHI Milan

Updated Category News Views 13

Kexing Biopharm's Showstopper Moment in Milan Call it a strategic blowout or just audacious timing—Kexing Biopharm's move at the CPHI Milan 2026 has painted a clear picture. From October 6th to 8th, Milan was the stage where Kexing rolled out its showcase, bragging about a pipeline that screams innovation and possibility. And let’s be honest, their timing couldn’t...

Continue Reading
Haag-Streit Debuts Innovative Octopus 910 Perimeter at AAO

Updated Category News Views 5

Now here's something that'll tickle your ophthalmologist's fancy—Haag-Streit USA has rolled out the Octopus 910, a slick piece of kit set to shake up visual field testing for glaucoma management. This time, they're getting in front of the competition, unveiling it at the Association for Research in Vision and Ophthalmology's 2026 shindig in New Orleans. With this new...

Continue Reading
Zoomlion Boosts Mining Gear Amid Global Revenue Surge

Updated Category News Views 10

An Ambitious Expansion Overhaul Alright, let's talk Zoomlion Heavy Industry Science & Technology Co., Ltd. They're not just making a splash; they're wading knee-deep into expanding their mining machinery operations and taking charge in international markets. You see, in the first half of 2026, this Chinese behemoth saw its mining machinery business skyrocket by over...

Continue Reading
Phoenix Scholar Examines AI and Institutional Trust

Updated Category News Views 7

A Thoughtful Look at Trust and Technology We're staring at an issue here that dives deep into the guts of how technology, AI in particular, is reshaping our professional landscape. The latest issue of the Phoenix Scholar, a publication from the University of Phoenix College of Doctoral Studies, is tackling big questions. It's that kind of brainy reading where you untangle...

Continue Reading
Tchah Sup Kim: A Retrospective at KCCNY in 2026

Updated Category News Views 6

A Glimpse into Tchah Sup Kim's Legacy Stumble into the world of Tchah Sup Kim (1940–2022) this fall at the Korean Cultural Center New York. Kim's posthumous retrospective, "The Key to a New World," brings together over 130 of his works alongside archival materials, offering a comprehensive dive into a mind that spent decades between New York and Korea. The exhibit,...

Continue Reading

Top 5 Most Recently Viewed Articles

Legal Actions Impacting Atkore Inc.: What You Need to Know

Updated Category News Views 278

Understanding the Recent Legal Developments for Atkore Inc. Recently, significant legal issues have emerged for Atkore Inc. (NASDAQ: ATKR), a prominent player in the electrical and industrial components market. Investors are urged to pay attention as a class action lawsuit has been filed that could affect their rights and investments. This legal action is based on serious...

Continue Reading
Cargojet's Upcoming Third Quarter Conference Call Details

Updated Category News Views 163

Cargojet's Upcoming Third Quarter Conference Call Cargojet Inc. has exciting news for its investors as it prepares to announce its financial results for the third quarter. The results will be shared with the public after market close on a scheduled day in November. This release is eagerly anticipated as it provides insight into the company’s performance and future...

Continue Reading
Analyzing Amgen's Stock Performance and P/E Ratio Trends

Updated Category News Views 172

Understanding Amgen Inc.'s Current Stock Situation As of now, Amgen Inc. (NASDAQ: AMGN) shares are trading at $299.82, reflecting a modest increase of 0.82% for the current session. Over the past month, the stock has appreciated by 5.71%, while it has seen a decline of 5.55% over the past year. These fluctuations prompt investors to consider whether the stock might be...

Continue Reading
DoubleDown Interactive's Strategic Moves and Investor Engagement

Updated Category News Views 157

DoubleDown Interactive's Commitment to Investors DoubleDown Interactive (NASDAQ: DDI) is making significant strides in engaging with the investor community. As a prominent developer and publisher of digital games across mobile and web platforms, the company is preparing to showcase its initiatives and innovations at two major institutional investor conferences. Key...

Continue Reading
Michael Ward Takes the Lead in Grosvenor's Development Finance

Updated Category News Views 224

Michael Ward Takes the Helm of Grosvenor's SDF Programme Grosvenor, a leading international property firm, has recently named Michael Ward the Managing Director of its Structured Development Finance (SDF) Programme. This exciting announcement is a key development for the company as it strengthens its commitment to promoting growth in North America's urban property...

Continue Reading